- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
NTRK Gene Fusions | Clinical
Testing for NTRK Gene Fusions in the Community Setting
September 21, 2022
Alexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.
FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer
September 14, 2022
The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.
Looking at the Future of Larotrectinib in NTRK Fusion+ Lung Cancer
September 14, 2022
David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.
Larotrectinib Demonstrates Robust Responses in TRK Fusion-Positive Lung Cancer
September 06, 2022
In an interview with Targeted Oncologyy, David S. Hong, MD, discussed an updated analysis of larotrectinib and the data supporting the agent for the treatment of TRK fusion-positive lung tumors.
Choosing Larotrectinib vs Entrectinib to Treat NTRK Fusion+ Lung Cancer
September 04, 2022
David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.
FDA-Approved and Investigational TRK Inhibitors
June 22, 2022
Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene fusion-positive cancers.
Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors
June 07, 2022
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.
Larotrectinib Exhibits Rapid and Sustained HRQoL Improvement in TRK Fusion Cancers
June 07, 2022
Continued robust quality of life improvement documented in an expanded dataset of patients with TRK fusion cancer treated with larotrectinib are consistent with the rapid onset of clinical benefit and favorable safety profile of larotrectinib in both adult and pediatric patients.
Larotrectinib Extends Survival With Favorable Safety After Long-Term Follow-Up in TRK Fusion Lung Cancer
June 06, 2022
Patients with advanced lung cancer harboring neurotrophic tyrosine receptor kinase gene fusions treated with larotrectinib demonstrated positive efficacy and safety.
Larotrectinib Continues to Show Promise in Pediatric TRK Fusion-Positive Cancer
June 06, 2022
Rapid and durable responses continue to be demonstrated with larotrectinib in pediatric patients with tropomyosin receptor kinase fusion-positive cancer.